Norfloxacin: Its potential in clinical practice

The American Journal of Medicine

Volumn 82, Issue 6 SUPPL. 2, 1987, Pages 27-34

  Lee, Craig ^a   Ronald, Allan R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ERYTHROMYCIN; NORFLOXACIN; ROSOXACIN; TETRACYCLINE;

DIARRHEA; DRUG INDICATION; GASTROENTERITIS; HUMAN; INFECTION PREVENTION; NEISSERIA GONORRHOEAE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SHORT SURVEY; URINARY TRACT INFECTION;

BACTERIAL INFECTIONS; DIARRHEA; GONORRHEA; HUMAN; NEUTROPENIA; NORFLOXACIN; TRAVEL; URINARY TRACT INFECTIONS;

EID: 0023614789     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(87)90615-2     Document Type: Article

References (60)

1. Norfloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
2. A critical evaluation of nalidixic acid in urinary tract infections
3. Resistance to nalidixic acid
4. Epidemiologic features of urinary infections due to Enterobacteriaceae resistant to nalidixic acid and trimethoprim
5. A comparison of the efficacy of nalidixic acid and cephalexin in bacteriuric women and their effect on fecal and periurethral carriage of Enterobacteriaceae
6. Recurrent urinary tract infections: prevention by prophylactic antibiotics after sexual intercourse
7. Recurrent urinary tract infections in premenopausal women: prophylaxis based on an understanding of the pathogenesis
8. Comparative in vitro activity of norfloxacin against urinary tract pathogens
9. Therapy for acute cystitis in adult women: randomized comparison of single-dose sulfisoxazole vs. trimethoprim/sulfamethoxazole
10. Advances in the treatment of urinary tract infection
11. Recurrent urinary tract infections in men
12. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora
13. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections
14. Multiclinic study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections
15. Efficacy of norfloxacin in urinary tract infections: biological effects on vaginal and fecal flora
16. Prophylaxis of recurrent urinary tract infection in female patients: efficacy of low-dose, thrice-weekly therapy with trimethoprim-sulfamethoxazole
17. Long-term therapy for chronic bacteriuria in men
18. Norfloxacin penetration into human renal and prostatic tissues
19. Urinary infection and complications during clean intermittent catheterization following spinal cord injury
20. Penicillinase-producing Neisseria gonorrhoeae: the continuing challenge (abstr 15)
21. Spectinomycin resistant penicillinase-producing Neisseria gonorrhoeae (abstr 138)
22. Spectinomycin resistant beta-lactamase producing Neisseria gonorrhoeae
23. Antimicrobial resistance of Neisseria gonorrhoeae in Bangkok: is single-drug treatment passe?
24. A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance)
25. Chromosomally mediated resistance in Neisseria gonorrhoeae in the United States: results of surveillance and reporting, 1983–1984
26. Norfloxacin disposition after sequentially increasing oral doses
27. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography
28. Comparative in vitro activity of MK 0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae
29. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae
30. Comparative in-vitro activity of norfloxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae
31. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin
32. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis
33. Fever in pediatric and young adult patients with cancer
34. Management of infections in leukemia and lymphoma
35. Neutropenia, fever, and infection
36. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens
37. Gram-negative bacillary colonization and bacteremia in the compromised host
38. Infection in acute nonlymphocytic leukemia: the alimentary tract as a major source of pathogens
39. Infection prevention in acute non-lymphocytic leukemia: laminar air flow room reverse isolation with oral non-absorbable antibiotic prophylaxis
40. Chemoprophylaxis of bacterial infections in granulocytopenic patients
41. Infection in acute leukemic patients receiving oral non-absorbable antibiotics
42. The fate of ingested Pseudomonas aeruginosa in normal persons
43. Colonization resistance of the digestive tract in mice during systemic antibiotic treatment
44. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients
45. Prevention of infection by trimethoprim/sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia
46. Selective suppression of alimentary tract microbial flora as prophylaxis during granulocytopenia
47. Prophylactic trimethoprim/sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial
48. Failure of oral trimethoprim/sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia
49. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim/sulfamethoxazole
50. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients
51. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim/sulfamethoxazole vs nalidixic acid
52. Comparison of nalidixic acid to trimethoprim/sulfamethoxazole for infection prophylaxis in neutropenic cancer patients
53. Microbial modulation of the intestinal tract (abstr 772)
54. Double-blind randomized trial of oral prophylactic norfloxacin on infection in acute leukemia (abstr 149)
55. Norfloxacin vs trimethoprim/sulfamethoxazole for infection prevention in patients with acute leukemia (abstr 150)
56. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients
57. Antimicrobial prophylaxis against infection in neutropenic patients
58. Antimicrobial agents in the prevention of travellers' diarrhea
59. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis
60. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type I in adults